Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Lenvatinib
100%
Real-World Data
50%
Bevacizumab
50%
Atezolizumab
50%
Liver Function
34%
Overall Survival
25%
Progression Free Survival
24%
Bilirubin
18%
Albumin
18%
Electrocorticography
12%
Decompensated Liver Cirrhosis
11%
Liver Disease
11%
Adverse Event
6%
Prognostic Factor
6%
Side Effect
6%
Treatment Group
5%
Metabolic Dysfunction-Associated Steatotic Liver Disease
5%
Systemic Therapy
5%
Survival Rate
5%
Immunotherapy
5%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Lenvatinib
100%
Bevacizumab
50%
Atezolizumab
50%
Overall Survival
25%
Progression Free Survival
24%
Albumin
18%
Bilirubin
18%
Liver Disease
16%
Decompensated Liver Cirrhosis
11%
Adverse Event
6%
Side Effect
6%
Immunotherapy
5%
Systemic Treatment
5%
Treatment Group
5%
Survival Rate
5%
Nursing and Health Professions
Bevacizumab
50%
Atezolizumab
50%
Lenvatinib
50%
Liver Cell Carcinoma
50%
Liver Disease
16%
Decompensated Liver Cirrhosis
11%
Treatment Group
5%
Progression Free Survival
5%
Bilirubin
5%
Health Care Quality
5%
Systemic Therapy
5%
Immunotherapy
5%
University Hospital
5%
Albumin
5%
Survival Rate
5%